OBJECTIVE: To explore the potential active ingredients and possible mechanism of Renshen Guben oral liquid in the treatment of breast cancer by network pharmacology and molecular docking technology. METHODS: The active ingredients and potential targets in Renshen Guben oral liquid were obtained by Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform

BATMAN-TCM and other databases. Related disease targets of breast cancer were obtained from databases such as Human Mendelian Inheritance Omnibus and DigSee. The intersection targets of potential targets and related disease targets were imported into the STRING website for protein-protein interaction analysis

and the obtained data were imported into Cytoscape 3.8.2 software for module analysis by using the MCODE plug-in. And the representative targets were screened for gene ontology functional enrichment analysis（GO） and Kyoto Encyclopedia of Genes and Genomes pathway（KEGG） enrichment analysis by Metascape and other software. Cytoscape 3.8.2 software was used to construct “compound-target” “traditional Chinese medicine-compound-target-pathway” and other networks. The core target was extracted for molecular docking with corresponding compounds. RESULTS: 448 common targets of Renshen Guben oral liquid and breast cancer were screened. The key targets included SRC

STAT3

HSP90 AA1

PIK3 R1

Akt1

EGFR and ESR1. GO and KEGG enrichment analysis showed that the treatment of breast cancer by Renshen Guben oral liquid was mainly related to biological processes such as cellular response to nitrogen compound

cellular response to organic cyclic compound and MAPK cascade. Molecular docking results showed that the minimum binding energy between the core target and the corresponding compounds was MoreReset